Evidence map›Paper›PMID 23258574›Full record

Trial reportCirculation. Heart failure2013

Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.

Mathew S Maurer, Sergio Teruya, Bibhas Chakraborty, Stephen Helmke, Donna Mancini

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Heart failure, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00286182 (Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00286182 phase2completednot on this map

Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status

TypeinterventionalSponsorMathew S. MaurerRan2007 to 2012Enrolled56ConditionsAnemiaArmsErythropoietin alpha, Placebo
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. The treatment of chronic anemia in heart failure: a global approach.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Review
  18. Review
  19. Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mathew S MaurerColumbia University Medical Center, New York, NY, USA. msm10@columbia.edu
Sergio Teruya
Bibhas Chakraborty
Stephen Helmke
Donna Mancini
Columbia University Irving Medical Center · US

Funding

Pathophysiology of Heart Failure with a Normal Ejection Fraction in the ElderlyR01AG027518 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAURER, MATHEW S · 2007 to 2010
$2.1M
Midcareer Mentoring Award for Patient Oriented Research in Geriatric CardiologyK24AG036778 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAURER, MATHEW S · 2010 to 2020
$1.6M
NIA NIH HHS K24 AG036778NIA NIH HHS R01 AG027518
6 · The paper itself

Abstract

backgroundAnemia is a common comorbidity in older adults with heart failure and a preserved ejection fraction and is associated with worse outcomes. We hypothesized that treating anemia with subcutaneous epoetin alfa would be associated with reverse ventricular remodeling and improved exercise capacity and health status compared with placebo. METHODS AND

resultsProspective, randomized, single-blind, 24-week study with blinded end point assessment among anemic (average hemoglobin of 10.4±1 g/dL) older adult patients (n=56; 77±11 years; 68% women) with heart failure and a preserved ejection fraction (ejection fraction=63±15%; B-type natriuretic peptide=431±366 pg/mL) was conducted. Treatment with epoetin alfa resulted in significant increases in hemoglobin (P<0.0001). Changes in end-diastolic volume (-6±14 versus -4±16 mL; P=0.67) at 6 months did not differ between epoetin alfa and placebo, but declines in stroke volume (-5±8 versus 2±10 mL; P=0.09) without significant changes in left ventricular mass were observed. Changes in 6-minute walk distance (16±11 versus 5±12 m; P=0.52) did not differ. Although quality of life improved by the Kansas City Cardiomyopathy Questionnaire and the Minnesota Living with Heart Failure Questionnaire in both cohorts, there were no significant differences between groups.

conclusionsAdministration of epoetin alfa to older adult patients with heart failure and a preserved ejection fraction compared with placebo did not change left ventricular end-diastolic volume and left ventricular mass nor did it improve submaximal exercise capacity or quality of life. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT00286182.

Indexed as

AgedAged, 80 and overAge FactorsAnemiaBiomarkersChi-Square DistributionComorbidityEpoetin AlfaErythropoietinExercise TestExercise ToleranceFemaleHeart FailureHematinicsHemoglobinsHumansBiomarkersEpoetin AlfaErythropoietinHematinicsHemoglobinsNatriuretic Peptide, BrainRecombinant Proteins

Identifiers

PMID23258574
PMCPMC3606881
OpenAlexW2018604495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.